BeOne Medicines (ONC) Price & Analysis

Compare

839 Followers

ONC Stock Chart & Stats

$306.05

Market closed

$306.05

Day’s Range― - ―

52-Week Range$170.99 - $385.22

Previous CloseN/A

VolumeN/A

Average Volume (3M)317.50K

Market Cap

$34.93B

Enterprise Value$36.83B

Total Cash (Recent Filing)$4.04B

Total Debt (Recent Filing)$1.02B

Price to Earnings (P/E)588.8

Beta0.79

Next Earnings

Apr 01, 2026

EPS Estimate

1.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.09

Shares Outstanding109,663,280

10 Day Avg. Volume320,947

30 Day Avg. Volume317,503

Financial Highlights & Ratios

PEG Ratio1.09

Price to Book (P/B)5.84

Price to Sales (P/S)5.10

P/FCF Ratio-29.04

Enterprise Value/Market Cap1.05

Enterprise Value/Revenue7.41

Enterprise Value/Gross Profit8.59

Enterprise Value/Ebitda122.23

Forecast

1Y Price Target

$397.66

Price Target Upside29.93% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformanceManagement achieved their third quarter of GAAP profitability on the heels of strong sales and tight operational expense control, showing consistent financial performance.

Market PositionBrukinsa continues to capture share and is now the #1 BTKi in the US and globally.

Research And DevelopmentMultiple solid tumor assets have now achieved proof of concept data, underscoring the productivity of the research engine.

Bears Say

BeOne Medicines News

BeOne Medicines granted FDA Fast Track Designation for carcinoma candidate

BeOne Medicines (ONC) announced that the FDA has granted the company Fast Track Designation for BGB-B2033, its GPC3x4-1BB...

17h ago

ONC

Nurix Therapeutics price target raised to $30 from $24 at Mizuho

Mizuho raised the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $24 and keeps an Outperform...

9d ago

ONC

NRIX

BeOne Medicines announces new data on sonrotoclax

BeOne Medicines (ONC) announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as...

11d ago

ONC

BeOne Medicines says FDA grants Priority Review to NDA for sonrotoclax

BeOne Medicines (ONC) announced that the U.S. FDA has accepted and granted Priority Review to a New Drug...

23d ago

ONC

BeOne Medicines initiated with a Buy at Truist

Truist initiated coverage of BeOne Medicines (ONC) with a Buy rating and $400 price target The firm expect...

25d ago

ONC

BeOne Medicines Elevates Lai Wang to President, R&D Chief

BeOne Medicines ( ($ONC) ) has issued an announcement. On December 17, 2025, BeOne Medicines Ltd. appointed long-time...

17h ago

ONC

BeOne Medicines Secures $1 Billion Financing Agreement

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into...

30d ago

ONC

BeOne Medicines price target raised to $408 from $395 at RBC Capital

RBC Capital raised the firm’s price target on BeOne Medicines (ONC) to $408 from $395 and keeps an...

1M ago

ONC

Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets

Zymeworks ($ZYME) stock rallied 29% on Monday, after the clinical-stage biotechnology company announced positive Phase 3 trial results...

1M ago

ONC

JAZZ

BeOne Medicines: Buy Rating Driven by Robust Global Vision and Strong Financial Performance

Analyst Clara Dong of Jefferies maintained a Buy rating on BeOne Medicines, with a price target of $420.00....

1M ago

ONC

BeOne Medicines price target raised to $420 from $398 at Jefferies

Jefferies raised the firm’s price target on BeOne Medicines (ONC) to $420 from $398 and keeps a Buy...

1M ago

ONC

Jazz Pharmaceuticals price target raised to $205 from $185 at Morgan Stanley

Morgan Stanley analyst Sean Laaman raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $205 from $185...

1M ago

ONC

JAZZ

Zymeworks’ Ziihera shows efficacy in Phase 3 adenocarcinoma trial

Zymeworks (ZYME) announced positive topline results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera – zanidatamab-hrii – in...

1M ago

ONC

JAZZ

BeOne Medicines reports ‘positive’ results from Phase 3 HERIZON-GEA-01 trial

BeOne Medicines (ONC) announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA, a HER2-targeted bispecific...

1M ago

ONC

ONC FAQ

What was BeOne Medicines’s price range in the past 12 months?

BeOne Medicines lowest stock price was $170.99 and its highest was $385.22 in the past 12 months.

What is BeOne Medicines’s market cap?

BeOne Medicines’s market cap is $34.93B.

When is BeOne Medicines’s upcoming earnings report date?

BeOne Medicines’s upcoming earnings report date is Apr 01, 2026 which is in 103 days.

How were BeOne Medicines’s earnings last quarter?

BeOne Medicines released its earnings results on Nov 06, 2025. The company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $0.851 by $0.239.

Is BeOne Medicines overvalued?

According to Wall Street analysts BeOne Medicines’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does BeOne Medicines pay dividends?

BeOne Medicines does not currently pay dividends.

What is BeOne Medicines’s EPS estimate?

BeOne Medicines’s EPS estimate is 1.5.

How many shares outstanding does BeOne Medicines have?

BeOne Medicines has 109,663,280 shares outstanding.

What happened to BeOne Medicines’s price movement after its last earnings report?

BeOne Medicines reported an EPS of $1.09 in its last earnings report, beating expectations of $0.851. Following the earnings report the stock price went up 3.413%.

Which hedge fund is a major shareholder of BeOne Medicines?

Currently, no hedge funds are holding shares in ONC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

BeOne Medicines Stock Smart Score

Outperform

Fundamentals

Return on Equity

1.84%

Trailing 12-Months

Asset Growth

30.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

BeOne Medicines

BeOne Medicines (ONC) is a biopharmaceutical company focused on developing innovative therapies for patients with oncology-related conditions. The company operates in the biotechnology sector, specializing in the discovery and commercialization of novel cancer treatments that leverage advanced technologies and a deep understanding of cancer biology. BeOne Medicines aims to address unmet medical needs by developing targeted therapies that improve patient outcomes and quality of life.

BeOne Medicines (ONC) Earnings & Revenues

Historic Earnings Reports

ONC Company Deck

ONC Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlights strong financial performance with record revenue growth and a solid cash position. Significant achievements in R&D and FDA breakthrough designation for Sonro are positive. However, there are challenges in competitive markets and delays in some studies. Overall, the highlights outweigh the lowlights, indicating a positive outlook.View all ONC earnings summaries

ONC Stock 12 Month Forecast

Average Price Target

$397.66

▲(29.93% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"183":"$183","304":"$304","425":"$425","243.5":"$243.5","364.5":"$364.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":424,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$424.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":397.66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$397.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":362,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$362.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[183,243.5,304,364.5,425],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,335.6,342.40000000000003,349.20000000000005,356,362.8,369.6,376.40000000000003,383.2,390,396.8,403.6,410.4,417.2,{"y":424,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,335.6,340.37384615384616,345.14769230769235,349.9215384615385,354.6953846153846,359.4692307692308,364.24307692307696,369.0169230769231,373.79076923076923,378.5646153846154,383.33846153846156,388.1123076923077,392.8861538461539,{"y":397.66,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,335.6,337.63076923076926,339.6615384615385,341.69230769230774,343.7230769230769,345.75384615384615,347.7846153846154,349.81538461538463,351.84615384615387,353.8769230769231,355.9076923076923,357.9384615384615,359.96923076923076,{"y":362,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":205.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.71,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":224.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":332.04,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":310.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >